Skip to main content

Advertisement

Log in

The use of Cydectin® by wildlife carers to treat sarcoptic mange in free-ranging bare-nosed wombats (Vombatus ursinus)

  • Treatment and Prophylaxis - Original Paper
  • Published:
Parasitology Research Aims and scope Submit manuscript

Abstract

Wombats suffer from sarcoptic mange, a mite infection that ultimately leads to their death from secondary infections. In 2017, wildlife carers were granted legal approval to treat bare-nosed wombats (Vombatus ursinus) for sarcoptic mange in the field using 4 mL of topical Cydectin® per adult wombat. However, (limited) scientific field trials suggest approved protocols are inadequate which has been supported anecdotally by wildlife carers. Elucidating carer experience is key to holistically advancing understandings of sarcoptic mange treatment. We interviewed 18 wildlife carers regarding the use of Cydectin® to treat free-ranging adult wombats infected with sarcoptic mange which uncovered 43 detailed case studies for examination. Case studies revealed that wildlife carers have used 10–200-mL doses of topical Cydectin® to treat wombats to recovery. These results suggest there is no best-fit for treating wombats in the field, due to individual differences in observed levels of sarcoptic mange severity and differences in wombat behavior. Furthermore, wildlife carers suggested pour-on Cydectin® appeared non-toxic to wombats at rates as high as 200 mL per treatment. We recommend scientific trials should be undertaken to determine the impact and efficacy of the varying treatment regimens, including low and high doses of topical Cydectin® on bare-nosed wombats. This information is required for regulating authorities, and subsequently wildlife carers, and managers, to make fully informed decisions about wombat sarcoptic mange treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10

Similar content being viewed by others

Data availability

N/A

References

Download references

Acknowledgments

We would like to thank the many anonymous interviewees for their time.

Code availability

N/A

Funding

This work was funded by the Wombat Protection Society of Australia.

Author information

Authors and Affiliations

Authors

Contributions

Skelton conducted the interviews and curated the data. Skelton, Stannard, and Old designed the questions, analyzed the data, wrote the manuscript, and approved the final version of the manuscript.

Corresponding author

Correspondence to Julie M. Old.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethics approval

The questionnaire and methodology for this study was approved by the Western Sydney University Human Ethics committee (Ethics approval number: H13317).

Consent to participate

All those surveyed gave informed consent as outlined in the ethics approval.

Consent for publication

N/A

Additional information

Section Editor: Domenico Otranto

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

ESM 1

(DOCX 19 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Old, J.M., Skelton, C.J.A. & Stannard, H.J. The use of Cydectin® by wildlife carers to treat sarcoptic mange in free-ranging bare-nosed wombats (Vombatus ursinus). Parasitol Res 120, 1077–1090 (2021). https://doi.org/10.1007/s00436-020-07012-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00436-020-07012-8

Keywords

Navigation